MedTrace Logo

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

NCT02723084 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2021-07-16

Study results available
· View outcomes & findings →

Summary

The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.

Conditions

  • Chronic Hepatitis C Virus
  • Hepatitis C Virus

Interventions

DRUG

ABT-493/ABT-530

Co-formulated tablet

DRUG

sofosbuvir (SOF)

Tablet

DRUG

ribavirin (RBV)

Capsule

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc., MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-08
Primary Completion
2017-01-19
Completion
2017-03-24

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723084 on ClinicalTrials.gov